Blog
Daily evidence-led peptide research, regulatory news, expert digest and explainers. Every claim sourced; no AI tells.
Featured
EMA backs extending Mounjaro to children with type-2 diabetes
On 11 December 2025 the EMA's CHMP recommended extending Mounjaro's licensed indication to adolescents and children aged 10 and over with insufficiently controlled type-2 diabetes.
TRIUMPH-1: retatrutide hits 28.3% weight loss at 80 weeks
Eli Lilly's first general-obesity Phase 3 readout for retatrutide: 28.3% mean body-weight reduction at 80 weeks on 12 mg weekly. Larger than any SURMOUNT-5 figure to date.
Latest
15-PGDH and muscle loss on GLP-1 drugs
A Stanford mouse study finds that inhibiting 15-PGDH preserved muscle repair during semaglutide weight loss without reducing fat loss.
GLP-1 and GIP drugs in fat cells
A 2026 review maps what GLP-1 and dual GIP/GLP-1 agonists do inside human adipocytes, and finds most evidence still comes from rodent models.
Tirzepatide and Lithium Toxicity: A Case
A case report ties tirzepatide to lithium toxicity severe enough for hemodialysis. What GLP-1 patients on lithium should know.
Anti-dementia drugs in 2026: what works
A German review covers old-line dementia drugs, new amyloid antibodies, and why semaglutide failed in two large Alzheimer's trials.
Bacteriostatic water and the 28-day rule
Bacteriostatic water contains 0.9% benzyl alcohol to inhibit bacterial growth. Here is how long it lasts, what degrades it, and when to discard it.
CagriSema vs tirzepatide for obesity
A network meta-analysis of 25 trials ranked tirzepatide 15 mg and CagriSema as the top weight-loss treatments. But direct trial data tells a different story.
DNA-based GLP-1 delivery via MYO Technology
A single injection of plasmid DNA encoding GLP-1 produced sustained weight loss for over a year in obese mice. What the data shows.
Eli Lilly wins over Noom GLP-1 dose claims
The NAD recommended Noom drop its 'A Smaller Dose. A Smarter Start' tagline after Eli Lilly challenged the claim as unsupported by evidence.
GLP-1 drugs and lipedema: early evidence
A 2026 Dermatologic Surgery review found only two studies of GLP-1 receptor agonists in lipedema. The rationale is real, but the clinical evidence is thin.
Semaglutide in type 1 diabetes: Danish data
Danish registry data on 879 people with T1D who started semaglutide: HbA1c fell 0.52%, with no rise in hypoglycaemia or DKA hospitalisations.
Tirzepatide in Japan: real-world T2D data
A 324-patient Japanese study found tirzepatide cut HbA1c by 0.9 points and weight by 2.0 kg in 24 weeks of routine care.
Categories
Regulatory news
Agency actions, classification changes, enforcement letters and scheduling decisions across the EU, EEA, UK and US. Sourced to the primary regulator.
Trial readouts
What the latest Phase 2 and Phase 3 trials reported, the effect sizes that matter, and how to read the safety signals around them.
Expert digest
Credentialed experts on podcasts, in newsletters and at conferences, paraphrased with verbatim quotes, tier-coded for citation rigour.
Explainer
Evidence-led entry points for non-clinicians. What is a GLP-1 receptor agonist, what does ATC A10BX mean, why are some peptides legal in Russia but not the EU.
Comparison
Peptide-vs-peptide, country-vs-country, label-vs-grey-market. Methodology disclosed, conclusions tied to primary sources.
Vendor accountability
Counterfeit warnings, supply-chain incidents, Certificates of Analysis read in detail. We do not sell peptides and we do not promote vendors; we hold them to the same evidence bar as everyone else.
Methodology
How we score evidence depth, source recency and safety clarity. Behind-the-scenes editorial decisions. The reasoning, not just the result.
Country deep-dive
Single-country regulatory or market reports. How peptides actually move through Danish customs; what the BfArM said about a specific schedule shift; the German press response to a Mounjaro shortage.